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Aim: This study aimed to characterize the cellular basis of the platinum cytotoxicity of 
two novel platinum complexes, 3Pt and 1Pt, in comparison with that of cisplatin. 3Pt 
comprises anionic phosphate moieties, while 1Pt comprises neutral aromatic ligands.   
Methods: We compared the cytotoxic potency of 3Pt and 1Pt with that of cisplatin in 
osteosarcoma cell lines and an orthotopic mouse model. 
Results: The cytotoxic potency of 3Pt was markedly higher than that of cisplatin in all 
cell lines. Both novel platinum complexes showed a complete lack of cross resistance in 
cisplatin-resistant cells. Caffeine enhanced the cytotoxic potency of these novel 
platinum complexes, as observed for cisplatin. Apoptosis after drug administration was 
observed by DNA ladder formation and an annexin V/PI assay. DNA double-strand 
breaks were confirmed by phosphorylation of histone H2AX. In vivo, the antitumor 
activity of 3Pt and 1Pt was superior and similar, respectively, to that of cisplatin. Both 
novel platinum complexes exerted strong antitumor effects on osteosarcoma in vitro and 
in vivo. 
Conclusions: 3Pt may be an effective drug for the treatment of bone cancer because the 
PO3 moiety has a high affinity to bone, as exhibited by bisphosphonates, and is 
expected to decrease the incidence of side effects at extraskeletal sites and overcome 
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drug resistance. Cationic 1Pt may also be an effective antitumor drug because of its 
unique chemical structure and properties. Further investigations to detail the 
antitumor effects of these ionic Pt complexes on osteosarcoma are warranted. 
  
Key words: antitumor, bone-targeting platinum, cisplatin resistance, DNA interaction, 





For nearly 30 years, cisplatin has been one of the most effective antitumor agents 
available for the treatment of solid human tumors, including osteosarcoma [1]. However, 
some tumors are intrinsically resistant to cisplatin, and the development of resistance 
presents a major clinical barrier to effective treatment [2]. The efficacy of cisplatin is 
also limited by side effects such as dose-dependent renal toxicity and hematotoxicity.  
Osteosarcoma is a common malignant primary bone tumor that develops in patients 
aged 10–25 years, and its prognosis has improved significantly with advances in 
chemotherapy and local surgical control [3]. Since 1989, our research group has 
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published reports on caffeine-potentiated chemotherapy. Caffeine, a 
trimethyl-substituted xanthine, enhances the damage to cellular DNA and may inhibit 
the post-replication repair of sublethally damaged DNA [4]. Although the 5-year 
survival rate for nonmetastatic osteosarcoma in our department has improved to 90% 
with caffeine-potentiated chemotherapy [5-7], the prognoses of recurrent and metastatic 
osteosarcoma remains poor, with a long-term survival rate of >20% [8-11].    
Recently, we designed several platinum-based chemotherapy agents using new concepts 
[12]. Ionic platinum complexes were prepared to increase solubility and avoid platinum 
nephrotoxicity. Bisphosphonates, metabolically stable pyrophosphate analogs, are 
known for their bone-targeting properties and are used as therapeutic agents for bone 
diseases such as osteoporosis and bone metastasis [13,14]. Bisphosphonates have a 
strong affinity for calcium and show strong inhibition to osteoclastic resorption [15]. 
Therefore, we incorporated bisphosphonates into a platinum complex to target bone 
tissue. 
Another design was based on the structure of the cisplatin-DNA(-G-G-)-HMG (high 
mobility group) protein adduct [16], where aromatic ring stacking played an important 
role in adduct formation. The formed adduct is a key to escape attack by the DNA repair 
enzyme complex. Among the new protein targets, the proteasome may be a major target 
5 
 
of 1Pt because of its strong inhibitory capabilities [12]. The proteasome is involved in 
the regulation of nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-kappa B) activity and drives several anti-apoptotic activities and oncogenic factor 
expression [17].  
 
Objectives 
In this study, we analyzed the antitumor effects of two novel platinum complexes, 3Pt 
and 1Pt (figure 1) [12], on osteosarcoma and compared their efficacy with that of 
cisplatin both in vitro and in vivo. 
 
Materials and methods 
 
Ethics Statement 
The animal study was conducted in accordance with the Guidelines on the Care and Use 
of Laboratory Animals issued by Kanazawa University. The protocol was approved by 
the ethical committee of Kanazawa University (permit number: AP-112171). All 
surgeries were performed under sodium pentobarbital anesthesia. All efforts were made 
to minimize animal suffering, to decrease the number of animals used, and to utilize 
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possible alternatives to in vivo techniques. 
 
Drugs 
Both novel platinum drugs were synthesized by Professor Odani at the Division of 




3))] C12 synthesis 
For 1Pt synthesis, 0.42 g (1.3 mM) 
N-(9-anthracenylmethyl)-trimethylenediamine(AtC3)·2 HCl, 0.16 g (1.5 mM) Na2CO3 in 
10 mL H2O, and 5 mL EtOH were added to a suspension of 
Pt(5-methyl-1,10-phenanthroline(MP))CI2 (0.46 g, 1.0 mM) in 10 mL H20, and the 
mixture was stirred for approximately 3 h at 80°C. The black mixture was filtered while 
still hot to remove undissolved materials. After cooling to room temperature, the filtrate 
was evaporated till it decreased to 1–2 mL and acetone was added to the residue. After 
standing the residue overnight in a refrigerator, a pale yellow precipitate was formed, 
which was collected on a filter and dried under a vacuum to maintain the structure of 
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the metal complex, which yielded 0.49 g (62%). 
Elemental analysis: C31H30N4PtCl2·5 H2O·0.5 NaCl 
Observed: C, 44.14%; H, 4.30%; N, 6.26% 
Calculated: C, 43.64%; H, 4.81%; N, 6.57% 
Structure confirmations: The structure of 1Pt was indicated in Fig. 1 by H-NMR of 
1Pt(Pt-Mphen-AtC3 complex) showed 2 signals with same intensity,  which indicated 
two geometric isomers in square planner complex (cis-trans isomers). 
1H-NMR (D2O) 
8.85 (d, 1H), 8.75 (d, 1H), 8.66 (m, 4H), 8.36 (d, 1H), 8.28 (d, 2H), 8.16 (d, 1H), 7.94 (m, 
3H), 7.83 (t, 2H), 7.70 (m, 6H), 7.62 (s, 1H), 6.95 (m, 4H), 6.74 (m, 2H), 6.53 (m, 2H), 6.42 
(m, 2H), 5.43 (d, 2H), 3.62 (m, 2H), 3.44 (m, 2H), 3.28 (m, 2H), 3.03 (m, 2H), 2.73 (s, 3H), 
2.67 (s, 3H), 2.51 (m, 4H). 
 
13C-NMR (D2O) 
19.96(1C) , 27.05(1C) , 45.62(1C) , 53.19(1C) , 55.93(1C) , 
124.86(1C), 125.51(1C), 126.57(2C) , 127.80(3C) , 131.07(3C) , 132.12(3C) ,  
138.07(1C) , 140.12(1C) , 142.20(1C) , 144.69(1C), 145.56(1C), 146.49(1C) , 147.12(2C) , 







For 3Pt synthesis, Ag(NO3) (0.01 g, 0.07 mM) was dissolved in 1 mL H2O and added to 
K2PtCl4 (0.01 g, 0.03 mM) in 2 mL H2O, and the mixture was stirred overnight. 
Pt(Pt(1R,2R-diaminocyclohexane(dach)) (myo-inositol-1,2,3,4,5,6-hexakisphosphate 
(IP6))·10 Na·14 H2O (0.10 g, 0.07 mM) in 1 mL H2O was added to the solution and 
stirred for 2–3 days at 50°C. After removal of AgCl by filtration, the filtrate was 
evaporated and MeOH was added to the residue. The off-white powder was collected 
and dried under a vacuum to maintain the structure of the metal complex, which 
yielded 0.06 g (50%). 
Elemental analysis: C16H78N4O65P6Pt3Na18 (Pt(Pt(dach)IP6)2·18 Na·2 CH3OH·15 H2O)           
Observed: C, 10.90%; H, 2.75%; N, 1.96% 
Calculated: C, 11.30%; H, 3.17%; N, 1.83% 
Structure confirmations: The structure of 3Pt was indicated in Fig. 1 by P-NMR which 
showed 6 signals with same intensity and the two P signals at 2 and 3 in IP6 were not 




dach: 1.158(t,br,4H), 1.301(s,br, 4H), 1.578(s, br, 4H), 2.056(t, br, 4H). 2.406(m, br, 4H) ;  
IP6: 3.78(m, 2H), 4.03(m, 6H), 4.38(m, 4H) 
13C-NMR (D2O): 
dach: 26.78(4C), 34.63(4C), 65,77(4C),  
IP6: 73.88(1C), 74.52(1C), 76.19(4C), 77.70(2C), 78.55(2C), 79.64(1C), 80.31(1C) 
 
Cell lines and growth conditions 
The LM8, MG63, and 143B osteosarcoma cell lines were used for the experiments. The 
murine osteosarcoma cell line LM8 was provided by the RIKEN Tsukuba Institute 
BioResource Center (Ibaraki, Japan) through the National Bio-Resource Project of the 
Ministry of Education, Culture, Sports, Science, and Technology of Japan. All other cell 
lines were obtained from the American Type Culture Collection (Rockville, MD, USA). 
The osteosarcoma sublines LM8cisR, 143BcisR, and MG63cisR were established by 
exposing the cisplatin-sensitive osteosarcoma cell lines to successive increments in 
cisplatin concentrations. Resistance was stable in the absence of the selecting agent for 
at least 3 months. Cells were maintained in the log phase by supplementation with 
fresh medium 2–3 times/week. All cells were grown in Roswell Park Memorial Institute 
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1640 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 
μg/mL streptomycin. 
 
Growth inhibition assay 
Cellular viability was assessed using the 
2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium 
(WST-8) dye reduction assay. Briefly, cells were seeded in 96-well flat-bottomed 
microplates (100 μL/well) at 5 × 104 cells/mL, incubated for 24 h at 37°C, and exposed 
to various concentrations of the test compounds for 72 h. For each concentration, at 
least eight wells were used. After incubation with the test compounds, 10 μL of WST-8 
solution was added to each well. The microplates were further incubated for 3 h at 37°C, 
and absorption was measured using a microprocessor-controlled microplate reader 
(iMarkTM; Bio-Rad Laboratories, Hercules, CA, USA) at 450 nm. Half maximal 
inhibitory concentration (IC50) values were derived from dose–response curves. 
 
Apoptosis assay 
DNA fragmentation was analyzed by agarose gel electrophoresis. Osteosarcoma cells 
were exposed for 48 h to 12.5 μM of each test compound. DNA was extracted using the 
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Apoptotic DNA ladder kit (catalog no.: 11 835 264; Roche Applied Science, Indianapolis, 
IN, USA) according to the manufacturer’s instructions. The extracted DNA was 
electrophoresed on a 1.5% agarose gel containing 1 μg/mL of ethidium bromide at 100 V. 
The DNA fragments were visualized by exposing the gel to ultraviolet light and 
photographed. 
Flow cytometric assessment of annexin V binding to apoptotic cells was determined by 
assessing phosphatidylserine exposure to annexin V-fluorescein isothiocyanate (FITC) 
binding using the Annexin V-FITC staining kit (catalog no.: IM3546; Beckman Coulter, 
Fullerton, CA, USA) according to the manufacturer’s instructions. Cells (104) were 
analyzed in a flow cytometer (desk top cell sorter JSAN; Bay Bioscience Co., Ltd., 
Hyougo, Japan). Annexin V is used to identify cells in all stages of programmed cell 
death [18,19]. Propidium iodide (PI) exclusively stains cells with disrupted membranes 
and is used to identify late apoptotic and dead cells.  
 
Gamma-H2AX (γ-H2AX) immunofluorescence staining 
Cells were grown to 70% confluence in 4-well Lab-Tec Chamber Slides (Nunc, 
Naperville, IL, USA) and cultured for 24 h in the presence of 10 μM of each compound. 
At each time point, the cells were fixed. The slides were washed and incubated with 
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mouse monoclonal antibodies to histone γ-H2AX (dilution, 1:300; Upstate Biotechnology, 
Lake Placid, NY, USA), followed by incubation with Alexa Fluor 488-labeled goat 
antibodies conjugated to mouse immunoglobulin G (dilution, 1:700; Molecular Probes, 
Eugene, OR, USA). The slides were mounted in fluorescence mounting medium (Dako 
Cytomation, Hamburg, Germany), and the fluorescent signals were visualized using 
confocal laser scanning microscopy (BZ-9000; Keyence Corporation, Osaka, Japan). 
Three random fields, each containing at least 100 cells, were examined at 100× 
magnification. Nuclei containing ≥10 immunoreactive foci were counted as 
γ-H2AX-positive, and the percentage of positive cells was determined [20]. 
 
Orthotopic mouse model 
Animals 
Female nude mice (BALB/c-nu/nu) aged 4–6 weeks were purchased from Sankyo 
Laboratory Inc. (Toyama, Japan) and housed in a barrier facility under high-efficiency 
particulate air filtration. The mice were bred under germ-free and specific 
pathogen-free conditions. The animal study was conducted in accordance with the 
Guidelines on the Care and Use of Laboratory Animals issued by Kanazawa University. 
The protocol was approved by the ethical committee of Kanazawa University (permit 
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number: AP-112171). All surgeries were performed under sodium pentobarbital 
anesthesia. All efforts were made to minimize animal suffering, to reduce the number of 
animals used, and to utilize possible alternatives to in vivo techniques. 
 
Intratibial 143B transplantation  
For intratibial transplantation, cells were suspended in 10 μl of PBS containing 5 μg of 
MatrigelTM Basement Membrane Matrix (Becton Dickinson, Bedford, MA, USA) to 
prevent the suspension from leaking out. A suspension of 2 × 105 143B cells was 
implanted. All mice were checked and weighed daily, and tumors were measured once 
weekly using digital calipers. Two weeks after transplantation, mice were treated 
intraperitoneally with cisplatin (20 μM/kg), 1Pt (20 μM/kg), 3Pt (15 μM/kg), or normal 
saline (n = 8 each). We administered the compounds 1 day per week. Treatments were 
repeated weekly for 3 weeks. Six weeks after transplantation, all mice were sacrificed. 
 
Primary tumor growth 
Tumor volumes were calculated using the following equation: volume = 4π 
(A/2)(B/2)(C/2)/3, where A is the width (average distance in the medial–lateral plane), B 
is the length (average distance in the proximal–distal plane), and C is the width 
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(average distance in the anterior–posterior plane). 
 
Statistical analysis 
Data are presented as means ± standard deviation and were compared between groups 
using the unpaired Student’s t-test. A P-value of <0.05 was considered statistically 
significant. 
 
Results   
Cytotoxicity 
The cytotoxic activity of cisplatin, 1Pt, and 3Pt was determined in the 143B, MG63, 
LM8, 143BcisR, MG63cisR, and LM8cisR osteosarcoma cell lines, which were incubated 
for 72 h with the platinum-based compounds. Cell survival was evaluated as described 
in the Materials and Methods section. Each compound significantly inhibited 
cisplatin-susceptible cell growth in a dose-dependent manner (Figure 2). The IC50 value 
of 3Pt was significantly lower than that of cisplatin, and the cytotoxic activity of each 
compound was potentiated by adding 1 mM caffeine (Table 1). Cisplatin resistance was 
approximately 2.85-fold, with IC50 values of LM8 and LM8cisR cells. The resistance 
index (RI) was 2.85 for LM8cisR, 1.83 for 143BcisR, and 4.17 for MG63cisR (Figure 3, 
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Table 2). 3Pt potency was markedly higher than cisplatin potency in LM8, 143B, and 
MG63 cells, whereas 1Pt and 3Pt completely lacked cross-resistance in LM8cisR, 
143BcisR, and MG63cisR cells. 
 
Apoptosis induction 
Treatment with each platinum complex for 48 h resulted in DNA ladder formation 
(Figure 4). After the 24-h treatment, cisplatin and 1Pt demonstrated early apoptosis at 
a 10-μM concentration, whereas 3Pt showed early and late apoptosis at lower 
concentrations compared with cisplatin (Figure 5). 
 
 γ-H2AX immunofluorescence staining 
The effect of cisplatin is induced through DNA damage [21]. Because the chemical 
structures of 1Pt and 3Pt are quite different from those of cisplatin, we determined 
whether 1Pt and 3Pt induced H2AX phosphorylation to yield γ-H2AX, a marker of DNA 
double-strand breaks. 143B, MG63, and LM8 cell exposure to 1Pt or 3Pt resulted in 
gradual γ-H2AX foci accumulation, similar to the effects of cisplatin (Figure 6A,B).  
 
Orthotopic mouse model 
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143B cells were transplanted intratibialy in nude mice. At 6 weeks, 143B tumor 
treatment with 3Pt resulted in the largest, most significant, and most effective decrease 
in tumor volume compared with no treatment. 1Pt demonstrated almost the same 
effects as those of cisplatin. There were no animal deaths in any group (Figure 7).  
 
Discussion 
Cisplatin received clinical approval in 1978 and remains as one of the most powerful 
drugs for the treatment of testicular and ovarian cancer since then. Widespread clinical 
cisplatin use for malignant tumors has prompted a search for new platinum agents. 
Currently, carboplatin and oxaliplatin are widely applied clinically, although their 
clinical use against osteosarcoma has been limited. Direct cisplatin analogs interact 
with DNA-processing proteins in a similar manner as the parent drug. Differences in 
antitumor activities and toxicities may be mediated by differences in pharmacokinetics 
or reactivity rather than increased DNA function inhibition. Platinum compounds that 
are structurally different from cisplatin may form different platinum-DNA adduct 
types; however, they exhibit a spectrum of clinical activity complementary to that of the 
parent drug, such as the two novel Pt drugs described here. 
In this study, the antitumor effects of the two novel platinum complexes were evaluated 
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against osteosarcoma cell lines and in an orthotopic mouse model. Each complex 
exhibited excellent organic and aqueous solution solubility.  
The results of the present study showed that both complexes demonstrated strong 
antitumor activity. The cytotoxic potency of 3Pt was markedly higher than that of 
cisplatin. The detection of apoptosis by annexin V-FITC revealed that 3Pt inhibited 
143B cell proliferation by increasing the apoptotic and necrotic cell number and that the 
apoptotic effect of cisplatin was weak.  
Some studies reported varied cytotoxicity levels depending on the Pt complex structure 
[22]. A recent review explained how small changes in molecular structure can cause 
profound differences in biological activity [23]. Traditionally, few platinum cation 
complexes possess antitumor effects. However, a recent study on charged trinuclear 
cation platinum BBR3464 revealed that charge incorporation into the linker backbone 
and hydrogen-bonding capacity increased DNA affinity [24]. These features contribute 
to different DNA binding, cellular uptake, and antitumor activities within the 
polynuclear platinum family. Since 3Pt is an unusual trinuclear anion complex, it is 
expected to involve specific drug–bone interactions. 
Cisplatin adducts and analogs distort DNA conformation [25,26], inhibit replication and 
transcription [27,28], and induce apoptosis or necrosis [29]. In addition, cisplatin 
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adducts are removed from DNA mainly by the nucleotide excision repair system [30]. 
Although changes in the association process with DNA may exist, 1Pt and 3Pt cause 
dose-dependent apoptosis, similar to cisplatin. H2AX phosphorylation after drug 
administration was also found to be time-dependent. 
Cisplatin efficacy against malignant tumors is limited because of resistance, either 
intrinsic or acquired. The mechanism underlying cisplatin resistance appears to be 
multifactorial because cancer cells can develop cisplatin resistance through changes in 
drug transport, enhanced drug detoxification systems, and changes in DNA repair 
mechanisms, such as increased nucleotide excision repair, interstrand crosslink repair, 
and mismatch repair loss [31,32]. Both novel platinum complexes showed efficacy 
against cisplatin-resistant cells. These antitumor activities against cisplatin-resistant 
cell lines suggested the ability to overcome the multiple mechanisms underlying 
cisplatin resistance. 3Pt was designed to target bone tissue and contains germinal 
bisphosphonate moieties for drug delivery, even if in low concentrations. Although 
antitumor activity at such low bisphosphonate concentrations may be nil, 3Pt is 
expected to be delivered to bone and bone-forming tumors more effectively. Because 3Pt 




Among the new protein targets, the proteasome may be a major target of 1Pt because of 
its strong inhibition [12]. 
1Pt showed strong antitumor activities by inducing DNA double-strand breaks, similar 
to cisplatin. However, 1Pt could not coordinate DNA because no ligand-exchange 
reaction was observed using H1-NMR on mixing 1Pt and guanosine 5′-phosphate (5′
-GMP). Then, the DNA event may occur after 1Pt interacts noncovalently with DNA and 
protein, as estimated in structurally similar Pt compounds such as 
Pt(56-dimethylphenanthroline)(s-dach) [33-35]. Among the possible protein targets, 
such as kinase, telomerase, and proteasome, the proteasome may be a major target of 
1Pt because Cu-phenanthroline (amino acid) exhibits a coordination structure similar to 
that of 1Pt and was reported to demonstrate proteasome inhibition [36]. The 
proteasome inhibitory activity has not received much attention because the proteasome 
inhibitor enhances the transport of the drug to the nuclei and is expected to act 
synergistically with the drug [37]. Proteasome inhibition by covalent bonding to the 
boronic acid moiety of the clinical drug bortezomib is well known; however, the problem 
of drug resistance led to the development of a noncovalent-type inhibitor [38]. 
Bortezomib, a boronic acid dipeptide, was the first proteasome inhibitor approved by the 
U.S. Food and Drug Administration for myeloma treatment [39]. The proteasome is the 
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primary component of the protein degradation pathway. Through the degradation of 
regulatory proteins, the proteasome serves as a central conduit for many cellular 
regulatory signals; therefore, it is an attractive therapeutic drug target. The NF-kappa 
B signaling pathway may be a critical target for proteasome inhibitors. This repression 
is released in response to cellular stresses that cause targeted proteasome-induced 
I-kappa B degradation to release NF-kappa B [40-44], which is rapidly translocated to 
the nucleus where it increases production of cytokines, including vascular endothelial 
growth factor, tumor necrosis factor, interleukin-1, interleukin-6, and cell adhesion 
molecules. NF-kappa B can also increase anti-apoptotic expression of Bcl-2 protein 
family members [45-48]. Dysregulation of NF-kappa B signaling is an important feature 
of malignancy [49,50], and proteasome inhibitors produce antitumor effects by causing 
direct tumor cell apoptosis and exerting effects on the tumor microenvironment, such as 
anti-angiogenesis. Furthermore, bortezomib suppresses growth and induces apoptosis 
in osteosarcoma both in vitro and in vivo [51]. Therefore, proteasome inhibitors are 
interesting drug candidates for the treatment of osteosarcoma, considering that 1Pt 






We developed two novel platinum complexes that exhibited powerful antitumor effects 
against osteosarcoma cell lines and in an orthotopic mouse model. Therefore, these 
novel Pt complexes may represent a new class of potent antisarcoma agents. In addition 
enhanced chemotherapy by caffeine addition was possible. However, further in vitro 
studies are required to unravel the putative mechanisms underlying their actions, 
including DNA interactions. 
Figure Legends 
Figure 1 
Structures of the novel platinum compound 1Pt and 3Pt 
 
Figure 2 
Growth inhibition assay of each platinum complex against LM8, MG63, and 143B cells 
Osteosarcoma cells were incubated with cisplatin, 1Pt, or 3Pt for 72 h and evaluated 
using the WST-8 assay. 
 
Figure 3 




Osteosarcoma cells were incubated with cisplatin, 1Pt, or 3Pt for 72 h and assessed by 
the WST-8 assay. 
 
Figure 4 
Agarose gel electrophoresis for analysis of DNA fragmentation induced by the platinum 
complexes  
Osteosarcoma cells were exposed to 12.5 μM of each compound for 48 h. DNA was 
extracted and electrophoresed in an agarose gel. The DNA fragments were then 
visualized by exposing the gel to ultraviolet light. 
 
Figure 5 
The annexin V-FITC/PI assay to assess apoptosis of 143B cells induced by the platinum 
complexes 
143B cells were exposed to each compound for 24 h, and flow cytometry assay was 





Formation of gamma-H2AX foci induced by the platinum complexes in 143B cells 
The cells were incubated with each platinum complex for 48 h, fixed, and subjected to 
immunofluorescence staining for γ-H2AX. 
 
Figure 6B 
Formation of gamma-H2AX foci induced by the platinum complexes in LM8, MG63 and 
143B cells. They were then fixed and subjected to immunofluorescence staining for 
gamma-H2AX and the percentage of cells containing gamma-H2AX foci was determined. 
Data are means±s.e. 
 
Figure 7 
In vivo antitumor effects of the platinum complexes 
143B cells were transplanted into the tibia of nude mice and allowed to form tumors, 
following which the mice were assigned to 1 of 4 treatment groups (control, cisplatin, 
1Pt, or 3Pt) as described in Materials and Methods section. Tumor volume was 
measured at the indicated time points after the onset of treatment. All data are 





IC50 value of cisplatin and 1Pt, 3Pt against LM8, MG63, and 143B cells with and 
without adding 1mM of caffeine. 
Osteosarcoma cells were incubated with either platinum complex with and without  
caffeine for 72 h and then assessed via the WST-8 assay 
 
Table 2 
IC50 value of cisplatin and 1Pt, 3Pt against LM8, MG63, 143B, LM8cisR, MG63cisR, 
143BcisR cells. 
RI(resistance index)=cisplatin-resistant/cisplatin-sensitive IC50. Osteosarcoma cells 
were incubated with cisplatin, 1Pt, or 3Pt for 72 h and assessed by the WST-8 assay. 
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Time (Weeks after transplantation) 
  CDDP IC50(µM) 1Pt IC50(µM) 3Pt IC50 (µM) 
 +CAF 1mM  +CAF 1mM  +CAF 1mM 
LM8 1.09±0.24 0.47±0.10** 3.38±0.49 1.46±0.29** 0.12±0.01 0.068±0.015** 
MG63 1.85±0.48 1.02±0.09** 3.40±0.47 2.32±0.20** 0.72±0.15 0.48±0.07** 
143B 2.19±0.15 1.24±0.10** 5.83±0.30 3.31±0.53* 0.62±0.07 0.48±0.08** 
Drug LM8 IC50(μM) LM8-cisR IC50(μM) RI MG63 IC50(μM) MG63-cisR IC50(μM) RI 143B IC50(μM) 143B-cisR IC50(μM) RI 
CDDP 1.20±0.06 3.41±0.10 2.85 1.09±0.06 4.53±0.21 4.17 1.00±0.03 1.83±0.10 1.83 
1Pt 2.72±0.18 2.74±0.13 1.01 2.47±0.12 2.41±0.11 0.97 2.10±0.05 1.97±0.10 0.93 
3Pt 0.050±0.006 0.049±0.004 0.98 0.173±0.014 0.178±0.021 1.03 0.091±0.007 0.078±0.007 0.85 
